Update on Genetic Screening
An FDA Approved Kit, Views on Early Diagnosis
Bibliographic Data
| ID | 21048852 |
|---|---|
| Authors | Joyce Bermel (corresponding author) |
| Year | 1983 |
| Volume | 13 |
| Issue | 5 |
| Pages | 3-4 |
| Publication date | 1983-10-01 |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | The Hastings Center Report (JOURNAL) |
| Journal identifiers | ISSN: 0093-0334 • E-ISSN: 1552-146X |
| Publisher | JSTOR (PUBLISHER) |
| DOI | 10.2307/3560565 |
| PMID | 11644083 |
| OpenAlex | W2419246687 |
| Language | EN |
| Citations received | 1 |
Recent developments in prenatal diagnosis and screening for congenital defects are summarized. The Food and Drug Administration has approved the unrestricted sale of alpha-fetoprotein test kits to medical personnel and laboratories. Critics of the FDA action fear that unregulated use of the kits, which detect the possibility of neural tube defects, will lead to abortions of normal fetuses if follow-up procedures are not conducted to confirm the diagnosis. Bermel also reports on an American survey that indicates a strong desire for prenatal testing among older women, and on a British study of parental attitudes towards newborn screening for Duchenne muscular dystrophy
Duchenne muscular dystrophy · Family medicine · Fetus · Food and drug administration · Genetic testing · Gynecology · Medical emergency · Pregnancy · Prenatal diagnosis · Prenatal screening · Psychiatry · Genomics and Rare Diseases · Medicine · Metabolism and Genetic Disorders · Neurogenetic and Muscular Disorders Research · Pediatrics
| Citations per year | 0.14 |
|---|---|
| Citation span | 2019 - 2019 (1) |
| Highly cited | No |